Prosecution Insights
Last updated: April 19, 2026
Application No. 18/536,630

ENDOSCOPIC EXAMINATION SUPPORT APPARATUS, ENDOSCOPIC EXAMINATION SUPPORT METHOD, AND RECORDING MEDIUM

Non-Final OA §103§DP
Filed
Dec 12, 2023
Examiner
YANG, QIAN
Art Unit
2677
Tech Center
2600 — Communications
Assignee
NEC Corporation
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
2y 7m
To Grant
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allow Rate
709 granted / 963 resolved
+11.6% vs TC avg
Strong +31% interview lift
Without
With
+31.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
34 currently pending
Career history
997
Total Applications
across all art units

Statute-Specific Performance

§101
15.3%
-24.7% vs TC avg
§103
48.3%
+8.3% vs TC avg
§102
21.2%
-18.8% vs TC avg
§112
11.1%
-28.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 963 resolved cases

Office Action

§103 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 1 and 4 – 8 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 9 – 10 and 7 – 8 of U.S. Patent Application 18/288,700. Although the claims at issue are not identical, they are not patentably distinct from each other because, as can be seen from the comparison table below independent claims of current application appears to be worded slightly different than the co-pending application. Regarding claim 1, Claim 1 of instant application Claim 1 of No. 18/288,700 An endoscopic examination support apparatus comprising: a memory configured to store instructions; and a processor configured to execute the instructions to: acquire an endoscopic video captured by an endoscope; detect a lesion candidate from the endoscopic video; generate a heat map which represents a lesion possibility of the lesion candidate included in the endoscopic video by a color; and superimpose and display an area where the lesion possibility is highest among areas in the heat map, on the endoscopic video in a first display mode, and superimpose and display an area where the lesion possibility is next highest among the areas in the heat map, on the endoscopic video in a second display mode, wherein the second threshold is larger than the first threshold, and wherein the second display mode has a higher transparency than the first display mode. An endoscopic examination support apparatus comprising: a memory configured to store instructions; and a processor configured to execute the instructions to: acquire an endoscopic video captured by an endoscope; detect a lesion candidate from the endoscopic video; generate a heat map which represents a lesion possibility of the lesion candidate included in the endoscopic video by a color; and superimpose and display an area where the lesion possibility is equal to or higher than a first threshold on the endoscopic video in a first display mode, and superimpose and display an area where the lesion possibility is equal to or higher than a second threshold on the endoscopic video in a second display mode, wherein the second threshold is larger than the first threshold, and wherein the second display mode has a higher transparency than the first display mode. Regarding claims 4 – 8 of instant application, they are corresponding to claims 9 – 10 and 7 – 8 of U.S. Patent Application 18/288,700, respectively. Claims 1 and 4 – 8 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 4 – 8 of U.S. Patent Application 18/530,375. Although the claims at issue are not identical, they are not patentably distinct from each other because, as can be seen from the comparison table below independent claims of current application appears to be worded slightly different than the co-pending application. Regarding claim 1, Claim 1 of instant application Claim 1 of No. 18/530,375 An endoscopic examination support apparatus comprising: a memory configured to store instructions; and a processor configured to execute the instructions to: acquire an endoscopic video captured by an endoscope; detect a lesion candidate from the endoscopic video; generate a heat map which represents a lesion possibility of the lesion candidate included in the endoscopic video by a color; and superimpose and display an area where the lesion possibility is highest among areas in the heat map, on the endoscopic video in a first display mode, and superimpose and display an area where the lesion possibility is next highest among the areas in the heat map, on the endoscopic video in a second display mode, wherein the second threshold is larger than the first threshold, and wherein the second display mode has a higher transparency than the first display mode. An endoscopic examination support apparatus comprising: a memory configured to store instructions; and a processor configured to execute the instructions to: acquire an endoscopic video captured by an endoscope; detect a lesion candidate from the endoscopic video; generate a heat map which represents a lesion possibility of the lesion candidate included in the endoscopic video by a color; and superimpose and display the lesion possibility on the endoscopic video in multiple display modes with different degree of transparency according to the lesion possibility. Regarding claims 4 – 8 of instant application, they are corresponding to claims 4 – 8 of U.S. Patent Application 18/530,375, respectively. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1 – 3, 5 and 7 – 8 is/are rejected under 35 U.S.C. 103 as being unpatentable over Kubota et al. (US Patent Application Publication 2021/0274999, IDS), hereinafter referred as Kubota, in view of Watanabe (US Patent Application Publication 2024/0029404, IDS), and in further view of Usuda (US Patent Application Publication 2021/0153720, IDS). Regarding claim 1, Kubota discloses an endoscopic examination support apparatus (Figs. 1 – 2) comprising: a memory configured to store instructions ([0028], ROM, RAM, storage device); and a processor ([0028], CPU) configured to execute the instructions to: acquire an endoscopic video captured by an endoscope ([0045], “The computation unit 22b acquires an image pickup signal from the endoscope 2 by the control unit 22a controlling driving of the light source apparatus 3 and driving of the image pickup device of the endoscope 2 and controlling the image pickup signal acquisition unit 21 in accordance with a set observation mode …”); detect a lesion candidate from the endoscopic video ([0046], “The lesion detection unit 33 in the support information generation unit 32 first detects a lesion area Ln from the observation image G1 by performing processing of applying an image discriminator which has acquired a function of being capable of discriminating a polyp image in advance through a learning method such as deep learning, to the observation image G1 (S2). The detection result of the lesion area Ln is output to the oversight risk analysis unit 34); generate a marker image which represents a lesion possibility of the lesion candidate included in the endoscopic video by a color (Figs. 6 – 7, [0083 – 0087]); and superimpose and display an area where the lesion possibility is highest among areas in the marker image, on the endoscopic video in a first display mode, and superimpose and display an area where the lesion possibility is next highest among the areas in the marker image, on the endoscopic video in a second display mode (Figs. 6 – 7, [0083 – 0087]), wherein the second threshold is larger than the first threshold ([0083 – 0087], oversight risk is high (threshold) than oversight risk is low). However, Kubota fails to explicitly disclose the apparatus wherein the marker image is a heat map; and wherein the second display mode has a higher transparency than the first display mode. However, in a similar field of endeavor Watanabe discloses an endoscope system (abstract). In addition, Watanabe discloses the system wherein generate and display a heat map for detected lesion ([0119]). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the invention of Kubota, and generate and display a heat map for detected lesion. The motivation for doing this is that utilizing a heat map to display a lesion possibility by color allows user to easily detect lesion candidate. Furthermore, in a similar field of endeavor Usuda discloses an endoscope system (abstract). In addition, Usuda discloses the system wherein the second display mode has a higher transparency than the first display mode (Fig. 7, [0075 - 0077, 0118 - 0119], teach display a lesion region with different transparency, wherein the second display mode as in fig. 7C has a higher transparency than the first display mode as in Fig. 7B). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the invention of Kubota in view of Watanabe, and the second display mode has a higher transparency than the first display mode. The motivation for doing this is that utilizing different transparency provides another way of distinction for different regions so that the Application of Kubota can be broadened. Regarding claim 2 (depends on claim 1), Usuda discloses the apparatus wherein the second display mode is different in transparency from the first display mode (Fig. 7, [0075 - 0077, 0118 - 0119], teach display a lesion region with different transparency, wherein the second display mode as in fig. 7C has a higher transparency than the first display mode as in Fig. 7B). Regarding claim 3 (depends on claim 2), Usuda discloses the apparatus wherein the second display mode has a higher transparency than the first display mode(Fig. 7, [0075 - 0077, 0118 - 0119], teach display a lesion region with different transparency, wherein the second display mode as in fig. 7C has a higher transparency than the first display mode as in Fig. 7B). Regarding claim 5 (depends on claim 1), Kubota discloses the apparatus wherein the processor is further configured to execute the instructions to: detect the lesion using a machine learning model learned in advance to estimate a lesion candidate included in the endoscopic image ([0037, 0061, 0069]). Regarding claims 7 – 8, they are corresponding to claim 1, thus, they are interpreted and rejected for a same reason set forth for claim 1. Claim(s) 4 and 6 is/are rejected under 35 U.S.C. 103 as being unpatentable over Kubota in view of Watanabe, in further view of Usuda and Kang et al. (US Patent Application Publication 2016/0027174, IDS), hereinafter referred as Kang. Regarding claim 4 (depends on claim 1), Kubota in view of Watanabe and in further view of Usuda fails to explicitly disclose the apparatus wherein a predetermined mark is superimposed and displayed at a position of a center or a center of gravity of an area having a highest lesion possibility. However, in a similar field of endeavor Kang discloses an image processing system (abstract). In addition, Kang discloses the system wherein a predetermined mark is superimposed and displayed at a position of a center or a center of gravity of an area having a highest lesion possibility (Figs. 3-4, [0078-0089], teach wherein a predetermine mark or cross mark 311 is superimposed and displayed at a position of a center of an area having a highest lesion possibility). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the invention of Kubota, and a predetermined mark is superimposed and displayed at a position of a center or a center of gravity of an area having a highest lesion possibility. The motivation for doing this is that utilizing a mark at the center allows the user to easily detect most accurate position any lesion candidates. Regarding claim 6 (depends on claim 4), Kang discloses the apparatus wherein the predetermined mark is displayed as a guide to a position of the lesion candidate for supporting decision making of a doctor (Figs. 3-4, [0078-0089] teach wherein a predetermine mark or cross mark 311 is displayed as a guide to a position of the lesion candidate for supporting decision making of a doctor). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to QIAN YANG whose telephone number is (571)270-7239. The examiner can normally be reached on Monday-Thursday 8am-6pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Bee can be reached on 571-270-5183. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /QIAN YANG/ Primary Examiner, Art Unit 2677
Read full office action

Prosecution Timeline

Dec 12, 2023
Application Filed
Oct 23, 2025
Non-Final Rejection — §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12598273
Camera Platform Incorporating Schedule and Stature
2y 5m to grant Granted Apr 07, 2026
Patent 12586560
ELECTRONIC APPARATUS, TERMINAL APPARATUS AND CONTROLLING METHOD THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12586239
SMART IMAGE PROCESSING METHOD AND DEVICE USING SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12579432
METHODS AND APPARATUS FOR AUTOMATED SPECIMEN CHARACTERIZATION USING DIAGNOSTIC ANALYSIS SYSTEM WITH CONTINUOUS PERFORMANCE BASED TRAINING
2y 5m to grant Granted Mar 17, 2026
Patent 12579686
Mixed Depth Object Detection
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+31.3%)
2y 7m
Median Time to Grant
Low
PTA Risk
Based on 963 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month